Login to Your Account

The New Target: URL's Gout Drug

Is Congress Second-Guessing More Drug Pricing Decisions?

By Karl Thiel

Friday, June 3, 2011
Here we go again. Last month, this column discussed the poor decision making that went into the pricing of Makena, the injection to prevent preterm labor in certain at-risk patients marketed by K-V Pharmaceutical Co., of St. Louis. (See BioWorld Today, May 3, 2011.) I could have added something about the gout drug Colcrys, approved in October 2009 and manufactured by URL Pharma Inc., of Philadelphia, which has caught similar flak . . . but I didn't, because the cases are actually quite different.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription